Management of lupus nephritis: An update

Journal of the American Society of Nephrology

Volumn 15, Issue 10, 2004, Pages 2694-2704

  Houssiau, Frédéric A ^a,b  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^b CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIGEN; DNA BINDING PROTEIN; HISTONE; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT;

ANTIBODY RESPONSE; APOPTOSIS; B LYMPHOCYTE; HELPER CELL; HUMAN; IMMUNE COMPLEX DEPOSITION; IMMUNE RESPONSE; KIDNEY BIOPSY; LUPUS ERYTHEMATOSUS NEPHRITIS; MEDICAL RESEARCH; NONHUMAN; NUCLEOSOME; PRIORITY JOURNAL; REVIEW; AUTOTRANSPLANTATION; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; FEMALE; HOSPITALIZATION; MALE; METHODOLOGY; MORTALITY; MULTIMODALITY CANCER THERAPY; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; STEM CELL TRANSPLANTATION; SURVIVAL; TREATMENT OUTCOME;

COMBINED MODALITY THERAPY; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUPUS NEPHRITIS; MALE; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; STEM CELL TRANSPLANTATION; SURVIVAL ANALYSIS; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME;

EID: 13444284218     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ASN.0000140218.77174.0A     Document Type: Review

References (110)

1. Cameron JS: Lupus nephritis. J Am Soc Nephrol 10: 413-424, 1999
2. Datta SK, Kaliyaperumal A: Nucleosome-driven autoimmune response in lupus. Pathogenic T helper cell epitopes and costimulatory signals. Ann N Y Acad Sci 815: 155-170, 1997
3. Rajagopalan S, Zordan T, Tsokos GC, Datta SK: Pathogenic anti-DNA autoantibody-inducing T helper cell lines from patients with active lupus nephritis: Isolation of CD4-8 T helper cell lines that express the gamma delta T-cell antigen receptor. Proc Natl Acad Sci U S A 87: 7020-2024, 1990
4. Adams S, Leblanc P, Datta SK: Junctional region sequences of T-cell receptor beta-chain genes expressed by pathogenic anti-DNA autoantibody-inducing helper T cells from lupus mice: Possible selection by cationic autoantigens. Proc Natl Acad Sci U S A 88: 11271-11275, 1991
5. Mohan C, Adams S, Stanik V, Datta SK: Nucleosome: A major immunogen for pathogenic autoantibody-inducing T cells of lupus. J Exp Med 177: 1367-1381, 1993
6. Desai-Mehta A, Mao C, Rajagopalan S, Robinson T, Datta SK: Structure and specificity of T cell receptors expressed by potentially pathogenic anti-DNA autoantibody-inducing T cells in human lupus. J Clin Invest 95: 531-541, 1995
7. Herrmann M, Voll RE, Kalden JR: Etiopathogenesis of systemic lupus erythematosus. Immunol Today 21: 424-426, 2000
8. Casciola-Rosen LA, Anhalt G, Rosen A: Autoantigens targeted in systemic lupus erythematosus are clustered in two populations of surface structures on apoptotic keratinocytes. J Exp Med 179: 1083-1086, 1994
9. Herrmann M, Voll RE, Zoller OM, Hagenhofer M, Ponner BB, Kalden JR: Impaired phagocytosis of apoptotic cell material by monocyte-derived macrophages from patients with systemic lupus erythematosus. Arthritis Rheum 41: 1241-1250, 1998
10. Baumann I, Kolowos W, Voll RE, Manger B, Gaipl U, Neuhuber WL, Kirchner T, Kalden JR, Hermann M: Impaired uptake of apoptotic cells into tingible body macrophages in germinal centers of patients with systemic lupus erythematosus. Arthritis Rheum 46: 191-201, 2002
11. Robson MG, Cook HT, Botto M, Taylor PR, Busso N, Salvi R, Pusey CD, Walport MJ, Davies KA: Accelerated nephrotoxic nephritis is exacerbated in Clq-deficient mice. J Immunol 166: 6280-6288, 2001
12. Bickerstaff MC, Botto M, Hutchinson WL, Herbert J, Tennent GA, Bybee A, Mitchell DA, Cook HT, Butler PJ, Walport MJ, Pepys MB: Serum amyloid P component controls chromatin degradation and prevents antinuclear autoimmunity. Nat Med 5: 694-697, 1999
13. Blanco P, Palucka AK, Gill M, Pascual V, Banchereau J: Induction of dendritic cell differentiation by IFN-alpha in systemic lupus erythematosus. Science 294: 1540-1543, 2001
14. Berden JH, Grootscholten C, Jurgen WC, van der Vlag J: Lupus nephritis: A nucleosome waste disposal defect? J Nephrol 15[Suppl 6]: S1-S10, 2002
15. Bruns A, Blass S, Hausdorf G, Burmester GR, Hiepe F: Nucleosomes are major T and B cell autoantigens in systemic lupus erythematosus. Arthritis Rheum 43: 2307-2315, 2000
16. Kramers C, Hylkema MN, van Bruggen MC, van de Lagemaat R, Dijkman HB, Assméann KJ, Smeenk RJ, Berden JH: Anti-nucleosome antibodies complexed to nucleosomal antigens show anti-DNA reactivity and bind to rat glomerular basement membrane in vivo. J Clin Invest 94: 568-577, 1994
17. van Bruggen MC, Walgreen B, Rijke TP, Tamboer W, Kramers K, Smeenk RJ, Monestier M, Fournie GJ, Berden JH: Antigen specificity of anti-nuclear antibodies complexed to nucleosomes determines glomerular basement membrane binding in vivo. Eur J Immunol 27: 1564-1569, 1997
18. van Bruggen MC, Kramers C, Walgreen B, Elema JD, Kallenberg CG, van der Born J, Smeenk RJ, Assmann KJ, Muller S, Monestier M, Berden JH: Nucleosomes and histones are present in glomerular deposits in human lupus nephritis. Nephrol Dial Transplant 12: 57-66, 1997
19. Waters ST, McDuffie M, Bagavant H, Deshmukh US, Gaskin F, Jiang C, Tung KS, Fu SM: Breaking tolerance to double stranded DNA, nucleosome, and other nuclear antigens is not required for the pathogenesis of lupus glomerulonephritis. J Exp Med 199: 255-264, 2004
20. Prokunina L, Castillejo-Lopez C, Oberg F, Gunnarsson I, Berg L, Magnusson V, Brookes AJ, Tentler D, Kristjansdottir H, Grondal G, Bolstad AI, Svenungsson E, Lundberg I, Sturfelt G, Jonssen A, Truedsson L, Lima G, Alcocer-Varela J, Jonsson R, Gyllensten UB, Harley JB, Alarcon-Segovia D, Steinsson K, Alarcon-Riquelme ME: A regulatory polymorphism in PDCD1 is associated with susceptibility to systemic lupus erythematosus in humans. Nat Genet 32: 666-669, 2002
21. Morel L, Croker BP, Blenman KR, Mohan C, Huang G, Gilkeson G, Wakeland EK: Genetic reconstitution of systemic lupus erythematosus immunopathology with polycongenic murine strains. Proc Natl Acad Sci U S A 91: 6670-6675, 2000
22. Lauwerys BR, Wakeland EK: The genetic of lupus nephritis. Lupus 2004, in press
23. Austin HA 3rd, Klippel JH, Balow JE, le Riche NG, Steinberg AD, Plotz PH, Decker JL: Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs. N Engl J Med 314: 614-619, 1986
24. Boumpas DT, Austin HA 3rd, Vaughn EM, Klippel JH, Steinberg AD, Yarboro CH, Balow JE: Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis. Lancet 340: 741-745, 1992
25. Gourley MF, Austin HA 3rd, Scott D, Yarboro CH, Vaughan EM, Muir J, Boumpas DT, Kuppel JH, Balow JE, Steinberg AD: Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis. A randomized, controlled trial. Ann Intern Med 125: 549-557, 1996
26. Fiehn C, Hajjar Y, Mueller K, Waldherr R, Ho AD, Andrassy K: Improved clinical outcome of lupus nephritis during the past decade: Importance of early diagnosis and treatment. Ann Rheum Dis 62: 435-439, 2003
27. Chan TM, Li FK, Tang CS, Wong RW, Fang GX, Ji YL, Lau CS, Wong AK, Tong MK, Chan KW, Lai KN: Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group. N Engl J Med 343: 1156-1162, 2000
28. Houssiau FA, Vasconcelos C, D'Cruz D, Sebastiani GD, de Ramon Garrido E, Danieli MG, Abramovicz D, Blockmans D, Mathieu A, Direskeneli H, Galeazzi M, Gul A, Levy Y, Petera P, Popovic R, Petrovic R, Sinico RA, Cattaneo R, Font J, Depresseux G, Cosyns JP, Cervera R: Immunosuppressive therapy in lupus nephritis: The Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum 46: 2121-2131, 2002
29. Contreras G, Pardo V, Leclercq B, Lenz O, Tozman E, O'Nan P, Roth D: Sequential therapies for proliferative lupus nephritis. N Engl J Med 350: 971-980, 2004
30. Ponticelli C, Moroni G: Flares in lupus nephritis: Incidence, impact on renal survival and management. Lupus 7: 635-638, 1998
31. El Hachmi M, Jadoul M, Lefebvre C, Depresseux G, Houssiau FA: Relapses of lupus nephritis: Incidence, risk factors, serology and impact on outcome. Lupus 12: 692-696, 2003
32. Illei GG, Austin HA, Crane M, Collins L, Gourley MF, Yarboro CH, Vaughan EM, Kuroiwa T, Danning CL, Steinberg AD, Klippel JH, Balow JE, Boumpas DT: Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis. Ann Intern Med 135: 248-257, 2001
33. Houssiau FA, Lefebvre C, Depresseux G, Lambert M, Devogelaer JP, Nagant de Deuxchaisnes: Trabecular and cortical bone loss in systemic lupus erythematosus. Br J Rheumatol 35: 244-247, 1996
34. Jardinet D, Lefebvre C, Depresseux G, Lambert M, Devogelaer JP, Houssiau FA: Longitudinal analysis of bone mineral density in pre-menopausal female systemic lupus erythematosus patients: Deleterious role of glucocorticoid therapy at the lumbar spine. Rheumatology 39: 389-392, 2000
35. Houssiau FA, N'Zeusseu Toukap A, Depresseux G, Maldague BE, Malghem J, Devogelaer JP, Vande Berg BC: Magnetic resonance imaging-detected avascular osteonecrosis in systemic lupus erythematosus: Lack of correlation with antiphospholipid antibodies. Br J Rheumatol 37: 448-453, 1998
36. Boumpas DT, Austin HA 3rd, Vaughan EM, Yarboro CH, Klippel JH, Balow JE: Risk for sustained amenorrhea in patients with systemic lupus erythematosus receiving intermittent pulse cyclophosphamide therapy. Ann Intern Med 119: 366-369, 1993
37. Mok CC, Lau CS, Wong RW: Risk factors for ovarian failure in patients with systemic lupus erythematosus receiving cyclophosphamide therapy. Arthritis Rheum 41: 831-837, 1998
38. Dooley MA, Hogan S, Jennette C, Falk R: Cyclophosphamide therapy for lupus nephritis: Poor renal survival in black Americans. Glomerular Disease Collaborative Network. Kidney Int 51: 1188-1195, 1997
39. Austin HA 3rd, Boumpas DT, Vaughan EM, Balow JE: High-risk features of lupus nephritis: Importance of race and clinical and histological factors in 166 patients. Nephrol Dial Transplant 10: 1620-1628, 1995
40. Lupus nephritis: Prognostic factors and probability of maintaining life-supporting renal function 10 years after the diagnosis. Gruppo Italiano per lo Studio della Nefrite Lupica (GISNEL). Am J Kidney Dis 19: 473-479, 1992
41. Moroni G, Ventura D, Riva P, Panzeri P, Quaglini S, Banfi G, Simonini P, Bader R, Meroni PL, Ponticelli C: Antiphospholipid antibodies are associated with an increased risk for chronic renal insufficiency in patients with lupus nephritis. Am J Kidney Dis 43: 28-36, 2004
42. Cervera R, Khamashta MA, Font J, Sebastiani GD, Gil A, Lavilla P, Mejia JC, Aydintug AO, Chwalinska-Sadowska H, de Ramon E, Fernandez-Nebro A, Galeazzi M, Valen M, Mathieu A, Houssiau F, Caro N, Alba P, Ramos-Casals M, Ingelmo M, Hughes GR; European Working Party on Systemic Lupus Erythematosus: Morbidity and mortality in systemic lupus erythematosus during a 10-year period: A comparison of early and late manifestations in a cohort of 1,000 patients. Medicine (Baltimore) 82: 299-308, 2003
43. Felson DT, Anderson J: Evidence for the superiority of immunosuppressive drugs and prednisone over prednisone alone in lupus nephritis. Results of a pooled analysis. N Engl J Med 311: 1528-1533, 1984
44. Bansal VK, Beto JA: Treatment of lupus nephritis: A meta-analysis of clinical trials. Am J Kidney Dis 29: 193-199, 1997
45. Flanc RS, Roberts MA, Strippoli GF, Chadban SJ, Kerr PG, Atkins RC: Treatment of diffuse proliferative lupus nephritis: A meta-analysis of randomized controlled trials. Am J Kidney Dis 43: 197-208, 2004
46. Jayne D, Rasmussen N, Andrassy K, Bacon P, Tervaert JW, Dadoniene J, Ekstrand A, Gaskin G, Gregorini G, de Groot K, Gross W, Hagen EC, Mirapeix E, Petterson E, Siegert C, Sinico A, Tesar V, Westman K, Pusey C; European Vasculitis Study Group: A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med 349: 36-44, 2003
47. Donadio JV Jr, Holley KE, Ferguson RH, Illstrup DM: Progressive lupus glomerulonephritis. Treatment with prednisone and combined prednisone and cyclophosphamide. Mayo Clin Proc 51: 484-494, 1976
48. Steinberg AD, Decker JL: A double-blind controlled trial comparing cyclophosphamide, azathioprine and placebo in the treatment glomerulonephritis. Arthritis Rheum 17: 923-937, 1974
49. Mok CC, Ho CT, Siu YP, Chan KW, Kwan TH, Lau CS, Wong RW, Au TC: Treatment of diffuse proliferative lupus glomerulonephritis: A comparison of two cyclophosphamide-containing regimens. Am J Kidney Dis 38: 256-264, 2001
50. Steinberg AD, Steinberg SC: Long-term preservation of renal function in patients with lupus nephritis receiving treatment that includes cyclophosphamide versus those treated with prednisone only. Arthritis Rheum 34: 945-950, 1991
51. Illei GC, Takada K, Parkin D, Austin HA, Crane M, Yarboro CH, Vaughan EM, Kuroiwa T, Danning CL, Pando J, Steinberg AD, Gourley MF, Klippel JH, Balow JE, Boumpas DT: Renal flares are common in patients with severe proliferative lupus nephritis treated with pulse immunosuppressive therapy: Long-term followup of a cohort of 145 patients participating in randomized controlled studies. Arthritis Rheum 46: 995-1002, 2002
52. Fraenkel L, Bogardus S, Concato J: Patient preferences for treatment of lupus nephritis. Arthritis Rheum 47: 421-428, 2002
53. Houssiau FA, D'Cruz DP, Haga HJ, Hughes GR: Short course of weekly low-dose intravenous pulse cyclophosphamide in the treatment of lupus nephritis: A preliminary study. Lupus 1: 31-35, 1991
54. D'Cruz D, Cuadrado MJ, Mujic F, Tungekar MF, Taub N, Lloyd M, Khamashta MA, Hughes GR: Immunosuppressive therapy in lupus nephritis. Clin Exp Rheumatol 15: 275-282, 1997
55. Haga HJ, D'Cruz D, Asherson R, Hughes GR: Short term effects of intravenous pulses of cyclophosphamide in the treatment of connective tissue disease crisis. Ann Rheum Dis 51: 885-888, 1992
56. Allison AC, Eugui EM: Mycophenolate mofetil and its mechanisms of action. Immunopharmacology 47: 85-118, 2000
57. Hauser IA, Renders L, Radeke HH, Sterzel RB, Goppelt-Struebe M: Mycophenolate mofetil inhibits rat and human mesangial cell proliferation by guanosine depletion. Nephrol Dial Transplant 14: 58-63, 1999
58. Blaheta RA, Leckel K, Wittig B, Zenker D, Oppermann E, Harder S, Scholz M, Weber S, Encke A, Markus BH: Mycophenolate mofetil impairs transendothelial migration of allogeneic CD4 and CD8 T-cells. Transplant Proc 31: 1250-1252, 1999
59. Lui SL, Chan LY, Zhang XH, Zhu W, Chan TM, Fung PC, Lai KN: Effect of mycophenolate mofetil on nitric oxide production and inducible nitric oxide synthase gene expression during renal ischaemia-reperfusion injury. Nephrol Dial Transplant 16: 1577-1582, 2001
60. Corna D, Morigi M, Facchinetti D, Bertani T, Zoja C, Remuzzi G: Mycophenolate mofetil limits renal damage and prolongs life in murine lupus autoimmune disease. Kidney Int 51: 1583-1589, 1997
61. Van Bruggen MC, Walgreen B, Rijke TP, Berden JH: Attenuation of murine lupus nephritis by mycophenolate mofetil. J Am Soc Nephrol 9: 1407-1415, 1998
62. Chan TM, Wong WS, Lau CS, Tsang EWK, Ji YL, Mok MY, Tong MKL, Wong AKM, Lai KN: Prolonged follow-up of patients with diffuse proliferative lupus nephritis (DPLN) treated with prednisolone and mycophenolate mofetil (MMF) [Abstract A1010]. J Am Soc Nephrol 12: 195A, 2001
63. Hu W, Liu Z, Chen H, Tang Z, Wang Q, Shen K, Li L: Mycophenolate mofetil vs cyclophosphamide therapy for patients with diffuse proliferative lupus nephritis. Chin Med J (Engl) 115: 705-709, 2002
64. Appel G, Ginzler EM, Radhakrishnan J, Aranow C, Buyon J, Dooley MA, Merrill JT, Petri M, Gilkeson G, Wallace D, Weisman M: Multicenter controlled trial of mycophenolate mofetil (MMF) as induction therapy for severe lupus nephritis (LN) [Abstract]. J Am Soc Nephrol 14: 38A, 2003
65. Jayne D, Passweg J, Marmont A, Farge D, Zhao X, Arnold R, Hiepe F, Lisukov I, Musso M, Ou-Yang J, Marsh J, Wulffraat N, Besalduch J, Bingham SJ, Emery P, Brune M, Fassas A, Faulkner L, Ferster A, Fiehn C, Fouillard L, Geromin A, Greinix H, Rabusin M, Saccardi R, Schneider P, Zintl F, Gratwohl A, Tyndall A; European Group for Blood and Marrow Transplantation; European League Against Rheumatism Registry: Autologous stem cell transplantation for systemic lupus erythematosus. Lupus 13: 168-176, 2004
66. Traynor AE, Schroeder J, Rosa RM, Cheng D, Stefka J, Mujais S, Baker S, Burt RK: Treatment of severe systemic lupus erythematosus with high-dose chemotherapy and haematopoietic stem-cell transplantation; a phase I study. Lancet 356: 701-707, 2000
67. Traynor AE, Barra WG, Rosa RM, Rodriguez J, Oyama Y, Baker S, Brush M, Burt RK: Hematopoietic stem cell transplantation for severe and refractory lupus. Analysis after five years and fifteen patients. Arthritis Rheum 46: 2917-2923, 2002
68. Petri M, Jones RJ, Brodsky RA: High-dose cyclophosphamide without stem cell transplantation in systemic lupus erythematosus. Arthritis Rheum 48: 166-173, 2003
69. Lewis EJ, Hunsicker LG, Lan SP, Rohde RD, Lachin JM: A controlled trial of plasmapheresis therapy in severe lupus nephritis. The Lupus Nephritis Collaborative Study Group. N Engl J Med 326: 1373-1379, 1992
70. Maloney DG, Grillo-Lopez AJ, White CA, Bodkin D, Schilder RJ, Neidhart JA, Janakiraman N, Foon KA, Liles TM, Dallaire BK, Wey K, Royston I, Davis T, Levy R: IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 90: 2188-2195, 1997
71. Looney RJ, Anolik J, Sanz I: B cells as therapeutic targets for rheumatic diseases. Curr Opin Rheumatol 16: 180-185, 2004
72. Leandro MJ, Edwards JC, Cambridge G, Ehrenstein MR, Isenberg DA: An open study of B lymphocyte depletion in systemic lupus erythematosus. Arthritis Rheum 46: 2673-2677, 2002
73. Anolik JH, Campbell D, Felgar RE, Young F, Sanz I, Rosenblatt J, Looney RJ: The relationship of FcγRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus. Arthritis Rheum 48: 455-459, 2003
74. Abetimus: Abetimus sodium, LJP 394. BioDrugs 17: 212-215, 2003
75. Furie RA, Cash JM, Cronin ME, Katz RS, Weisman MH, Aranow C, Liebling MR, Hudson NP, Berner CM, Coutts S, de Haan HA: Treatment of systemic lupus erythematosus with LJP 394. J Rheumatol 28: 257-265, 2001
76. Alarcon-Segovia D, Tumlin JA, Furie RA, McKay JD, Cardiel MH, Strand V, Bagin RG, Linnik MD, Hepburn B; LJP 394 Investigator Consortium: LJP 394 for the prevention of renal flare in patients with systemic lupus erythematosus: Results from a randomized, double-blind, placebo-controlled study. Arthritis Rheum 48: 442-454, 2003
77. Cardiel MH, for the LJP 394-90-09 Study Investigators Group: Randomized, placebo controlled, double blind phase III clinical trial for the evaluation of LJP 394 (abetimus sodium) in the treatment of patients with SLE who are at risk for renal flare. Ann Rheum Dis 62[Suppl]: 81, 2003
78. Davis JC Jr, Totoritis MC, Rosenberg J, Sklenar TA, Wofsy D: Phase I clinical trial of a monoclonal antibody against CD40-ligand (IDEC-131) in patients with systemic lupus erythematosus. J Rheumatol 28: 95-101, 2001
79. Kalunian KC, Davis JC Jr, Merrill JT, Totoritis MC, Wofsy D; IDEC-131 Lupus Study Group: Treatment of systemic lupus erythematosus by inhibition of T cell costimulation with anti-CD154: A randomized, double-blind, placebo-controlled trial. Arthritis Rheum 46: 3251-3258, 2002
80. Boumpas DT, Furie R, Manzi S, Illei GG, Wallace DJ, Balow JE, Vaishnaw A: BG9588 Lupus Nephritis Trial Group: A short course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis. Arthritis Rheum 48: 719-727, 2003
81. Grohmann U, Orabona C, Fallarino F, Vacca C, Calcinaro F, Falorni A, Candeloro P, Belladonna ML, Bianchi R, Fioretti MC, Puccetti P: CTLA-4-Ig regulates tryptophan catabolism in vivo. Nat Immunol 3: 1097-1101, 2002
82. Finck BK, Linsley PS, Wofsy D: Treatment of murine lupus with CTLA4Ig. Science 265: 1225-1225, 1994
83. Kremer JM, Westhovens R, Leon M, Di Giorgio E, Alten R, Steinfeld S, Russell A, Dougados M, Emery P, Nuamah IF, Williams GR, Decker JC, Hagerty DT, Moreland LW: Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. N Engl J Med 349: 1907-1915, 2003
84. Houssiau FA, Lefebvre C, Vanden Berghe M, Lambert M, Devogelaer JP, Renauld JC: Serum interleukin 10 titers in systemic lupus erythematosus reflect disease activity. Lupus 4: 393-395, 1995
85. Llorente L, Zou W, Levy Y, Richaud-Patin Y, Wijdenes J, Alcocer-Varela J, Morel-Fourrier B, Brouet JC, Alarcon-Segovia D, Galanaud P, Emilie D: Role of interleukin 10 in the B lymphocyte hyperactivity and autoantibody production of human systemic lupus erythematosus. J Exp Med 181: 839-844, 1995
86. Lauwerys BR, Garot N, Renauld JC, Houssiau FA: Interleukin-10 blockade corrects impaired in vitro cellular immune responses of systemic lupus erythematosus patients. Arthritis Rheum 43: 1976-1981, 2000
87. Gross JA, Johnston J, Mudri S, Enselman R, Dilln SR, Madden K, Xu W, Parrish-Novak J, Foster D, Lofton-Day C, Moore M, Littau A, Grossman A, Haugen H, Foley K, Blumberg H, Harrison K, Kindsvogel W, Clegg CH: TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease. Nature 404: 995-999, 2000
88. Zhang J, Roschke V, Baker KP, Wang Z, Alarcon GS, Fessler BJ, Bastian H, Kimberly RP, Zhou T: Cutting edge: A role for B lymphocyte stimulator in systemic lupus erythematosus. J Imunol 166: 6-10, 2001
89. Bennett L, Palucka AK, Arce E, Cantrell V, Borvak J, Banchereau J, Pascual V: Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J Exp Med 197: 711-723, 2003
90. Crow MK: Interferon-alpha: A new target for therapy in systemic lupus erythematosus ? Arthritis Rheum 48: 2396-2401, 2003
91. Lauwerys BR, Houssiau FA: Involvement of cytokines in the pathogenesis of systemic lupus erythematosus. Adv Exp Med Biol 520: 237-251, 2003
92. Llorente L, Richaud-Patin, Garcia-Padilla C, Claret E, Jakez-Ocampo J, Cardiel MH, Alcocer-Varela J, Grangeot-Keros L, Alarcon-Segovia D, Wijdenes J, Galanaud P, Emilie D: Clinical and biologic effects of anti-interleukin-10 monoclonal antibody administration in systemic lupus erythematosus. Arthritis Rheum 43: 1790-1800, 2000
93. Weening JJ, D'Agati VD, Schwartz MM, Seshan SV, Alpers CE, Appel GB, Balow JE, Bruijn JA, Cook T, Ferrario F, Fogo AB, Ginzler EM, Hebert L, Hill G, Hill P, Jennette JC, Kong NC, Lesavre P, Lockshin M, Looi LM, Makino H, Moura LA, Nagata M: The classification of glomerulonephritis in systemic lupus erythematosus revisited. J Am Soc Nephrol 15: 241-250, 2004
94. Balow JE, Austin HA 3rd: Therapy of membranous nephropathy in systemic lupus erythematosus. Semin Nephrol 23: 386-391, 2003
95. Hu W, Liu Z, Shen S, Li S, Yao X, Chen H, Li L: Cyclosporine A in treatment of membranous lupus nephropathy. Chin Med J (Engl) 116: 1827-1830, 2003
96. Moroni G, Maccario M, Banfi G, Quaglini S, Ponticelli C: Treatment of membranous lupus nephritis. Am J Kidney Dis 31; 681-686, 1998
97. Mok CC, Ying KY, Lau CS, Yim CW, Ng WL, Wong WS, Au TC: Treatment of pure membranous lupus nephropathy with prednisone and azathioprine: An open-label trial. Am J Kidney Dis 43: 269-276, 2004
98. Ferro ML, Karim MY, Abbs IC, D'Cruz DP, Khamashta MA, Hughes GRV: Mycophenolate mofetil: A potential treatment for reducing proteinuria associated with membranous lupus nephritis. Arthritis Rheum 48: S588, 2003
99. Remuzzi G, Chiurchiu C, Abbate M, Brusegan V, Bontempelli M, Ruggenenti P: Rituximab for idiopathic membranous nephropathy. Lancet 360: 923-924, 2002
100. Ruggenenti P, Chiurchiu C, Brusegan V, Abbate M, Perna A, Filippi C, Remuzzi G: Rituximab in idiopathic membranous nephropathy: A one-year prospective study. J Am Soc Nephrol 14: 1851-1857, 2003
101. Bruce IN, Gladman DD, Urowitz MB: Premature atherosclerosis in systemic lupus erythematosus. Rheum Dis Clin North Am 26: 257-278, 2000
102. Roman MJ, Shanker BA, Davis A, Lockshin MD, Sammaritano L, Simantov R, Crow MK, Schwartz JE, Paget SA, Devereux RB, Salmon JE: Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N Engl J Med 349: 2399-2406, 2003
103. Asanuma Y, Oeser A, Shintani AK, Turner E, Olsen N, Fazio S, Linton MF, Raggi P, Stein CM: Premature coronary-artery atherosclerosis in systemic lupus erythematosus. N Engl J Med 349: 2407-2415, 2003
104. Hahn BH: Systemic lupus erythematosus and accelerated atherosclerosis. N Engl J Med 349: 2379-2380, 2003
105. Bjornadal L, Yin L, Granath F, Klareskog L, Ekbom A: Cardiovascular disease a hazard despite improved prognosis in patients with systemic lupus erythematosus: Results from a Swedish population based study 1964-95. J Rheumatol 31: 713-719, 2004
106. Moroni G, Tantardini F, Ponticelli C: Renal replacement therapy in lupus nephritis. J Nephrol 16: 787-791, 2003
107. Briggs JD, Jones E: Renal transplantation for uncommon diseases. Scientific Advisory Board of the ERA-EDTA Registry. European Renal Association-European Dialysis and Transplant Association. Nephrol Dial Transplant 14: 570-575, 1999
108. Ward MM: Outcomes of renal transplantation among patients with end-stage renal disease caused by lupus nephritis. Kidney Int 57: 2136-2143, 2000
109. Goral S, Ynares C, Shappell SB, Snyder S, Feurer ID, Kazancioglu R, Fogo AB, Helderman JH: Recurrent lupus nephritis in renal transplant recipients revisited: It is not rare. Transplantation 75: 651-656, 2003
110. Ponticelli C: Treatment of lupus nephritis - The advantages of a flexible approach. Nephrol Dial Transplant 12: 2057-2059, 1997